Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion with up to every 8-week dosing after an initial monthly dosing period. The FDA also approved an every four-week dosing option for some patients who may benefit from resuming this dosing schedule across approved indications: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and RVO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron trading halted, news pending
- Regeneron announces EC approved Libtayo for adults with CSCC
- REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?
- Cathie Wood Sells AMD Stock, Pours Millions into These 2 Crypto Plays
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls